by Team Small News | Nov 12, 2025 | Aurobindo Pharma, Pharma
Motilal Oswal has recommended a “buy” rating for Aurobindo Pharma, with a target price of Rs 1350. The brokerage firm is optimistic about the company’s future prospects, driven by its strong product pipeline, increasing presence in the US market, and... by Team Small News | Nov 7, 2025 | Aurobindo Pharma, Pharma
Aurobindo Pharma, a leading pharmaceutical company, has released its consolidated financial results for the quarter ended September 2025. The company’s net sales for the quarter stood at Rs 8,285.70 crore, representing a year-over-year (Y-o-Y) growth of 6.28%....
by Team Small News | Nov 1, 2025 | Apollo Hospital, Aurobindo Pharma, Lupin, Pharma, Sun Pharma
The Indian corporate sector has reported earnings in line with expectations for the September quarter, boosting market sentiment. Several prominent companies, including Indian Oil Corporation, Adani Green Energy, and Hindustan Petroleum Corporation Limited, have... by Team Small News | Oct 11, 2025 | Aurobindo Pharma, Pharma
Aurobindo Pharma, a midcap pharmaceutical company, has recently undergone a change in evaluation, with technical indicators now reflecting a bearish outlook. The company’s technical trend has shifted from mildly bearish to bearish, as indicated by various... by Team Small News | Oct 8, 2025 | Aurobindo Pharma, Pharma
Auro Realty, the real estate division of the Aurobindo Group, is planning to raise ₹20 billion ($225.41 million) through a bond sale to finance a significant acquisition. The Aurobindo Group also owns Aurobindo Pharma, a prominent drug manufacturer. According to two...
by Team Small News | Sep 29, 2025 | Aurobindo Pharma, Cipla, Lupin, Pharma, Sun Pharma
The Indian pharmaceutical industry is facing a complex global trade landscape, with contrasting developments in China and the US. China has reduced import duties on Indian pharma products by 30%, effectively enabling near-zero-cost access, providing a significant...